National Trends in Cyclooxygenase-2 Inhibitor Use Since Market Release | Zendy

Carolanne Dai | Zendy; Randall S. Stafford | Zendy; G. Caleb Alexander | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

National Trends in Cyclooxygenase-2 Inhibitor Use Since Market Release

Author(s) -

Carolanne Dai,

Randall S. Stafford,

G. Caleb Alexander

Publication year - 2005

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/archinte.165.2.171

Subject(s) - rofecoxib , medicine , adverse effect , proportional hazards model , cox 2 inhibitor , ambulatory , cyclooxygenase , biochemistry , chemistry , enzyme

The withdrawal of rofecoxib has highlighted concerns regarding the safety of cyclooxygenase-2 (COX-2) inhibitors. In some patients COX-2 inhibitors may be safer than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs); however, the public health benefit of COX-2 inhibitors depends on their use in patients at higher than normal risk from NSAIDs. We examined trends in COX-2 inhibitor use based on risk for adverse events from NSAIDs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research